Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty.


Journal

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
ISSN: 1938-2723
Titre abrégé: Clin Appl Thromb Hemost
Pays: United States
ID NLM: 9508125

Informations de publication

Date de publication:
Historique:
entrez: 23 3 2021
pubmed: 24 3 2021
medline: 29 10 2021
Statut: ppublish

Résumé

Osteoarthritis (OA) is a chronic condition marked by joint pain, inflammation and loss of articular cartilage, that can be treated with total joint arthroplasty (TJA) at end stages. TJA is marked by post-operative inflammation, which directly effects levels of cartilage degradation biomarkers, proteoglycan-4 (PRG4) and matrix metalloproteinase-9 (MMP-9). PRG4 is a protective glycoprotein that is decreased in individuals with OA. MMP-9 is a matrix metalloproteinase that contributes to articular cartilage loss and is elevated in OA patients. It is upregulated by pro-inflammatory markers, such as IL-1, IL-6 and CRP. This study aims to elucidate the immediate post-operative changes in levels of PRG4, MMP-9, IL-6, CRP, and WBC in patients undergoing TJA to clarify the role of inflammation in recovery after surgery and in the overall pathogenesis of OA. Blood was collected at 3 time points (day 0, day 1 post-operatively, and days 5-7 post-operatively), from 63 patients undergoing TJA due to OA, and levels of these biomarkers were quantified. IL-6, CRP, WBC and MMP-9 were lowest at day 0, highest at day 1, and stabilized at an intermediate level at days 5-7. Meanwhile, PRG4 followed the opposite trend. These studies suggest that IL-6, CRP and WBC showed predictable fluctuations, with pro-inflammatory biomarkers upregulating MMP-9 and downregulating PRG4. Measuring these biomarkers may help expose the role of inflammation in the post-surgical recovery of TJA patients and in long-term pathogenesis of OA. These levels may help risk stratify patients pre-operatively and help develop individualized post-surgical plans.

Identifiants

pubmed: 33754883
doi: 10.1177/1076029621995569
pmc: PMC7995300
doi:

Substances chimiques

PRG4 protein, human 0
Proteoglycans 0
MMP9 protein, human EC 3.4.24.35
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076029621995569

Subventions

Organisme : NIAID NIH HHS
ID : T35 AI125220
Pays : United States

Références

Ann Rheum Dis. 2013 Apr;72(4):535-40
pubmed: 22580582
Surgery. 2016 Aug;160(2):443-53
pubmed: 27206334
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619828113
pubmed: 30754994
Arterioscler Thromb. 1994 Oct;14(10):1648-56
pubmed: 7918316
Sci Transl Med. 2013 Mar 13;5(176):176ra34
pubmed: 23486780
Clin Appl Thromb Hemost. 2017 Nov;23(8):967-972
pubmed: 28345356
J Biol Chem. 2008 Feb 22;283(8):4850-65
pubmed: 18065760
Int J Mol Sci. 2017 Mar 12;18(3):
pubmed: 28287489
Sci Rep. 2017 Oct 13;7(1):13149
pubmed: 29030641
BMC Cell Biol. 2007 May 07;8:14
pubmed: 17480240
Can J Physiol Pharmacol. 2015 Oct;93(10):879-86
pubmed: 26176332
Ther Adv Chronic Dis. 2012 Sep;3(5):219-29
pubmed: 23342237
Curr Rheumatol Rep. 2000 Dec;2(6):459-65
pubmed: 11123098
Biomed Res Int. 2014;2014:407518
pubmed: 25313362
Clin Orthop Relat Res. 2019 Jan;477(1):41-46
pubmed: 30794227
Front Biosci. 2006 Sep 01;11:3081-95
pubmed: 16720377
Arthritis Res Ther. 2017 May 8;19(1):89
pubmed: 28482921
Clin Appl Thromb Hemost. 2018 Sep;24(6):950-959
pubmed: 29683034
Mol Biol Rep. 2011 Jun;38(5):2879-85
pubmed: 20099082
Osteoarthritis Cartilage. 2004;12 Suppl A:S31-3
pubmed: 14698638
Osteoarthritis Cartilage. 2013 Sep;21(9):1179-84
pubmed: 23973128
Arthritis Res Ther. 2016 Apr 01;18:81
pubmed: 27039382
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620964864
pubmed: 33350314
Knee. 2019 Dec;26(6):1379-1385
pubmed: 31575511
JNMA J Nepal Med Assoc. 2009 Apr-Jun;48(174):144-8
pubmed: 20387356

Auteurs

Hannah Slovacek (H)

Department of Pathology and Laboratory Medicine, 25815Loyola University Medical Center, Maywood, IL, USA.

Rajan Khanna (R)

Department of Pathology and Laboratory Medicine, 25815Loyola University Medical Center, Maywood, IL, USA.

Pavel Poredos (P)

Medical Clinic Division of Vascular Medicine, University Medical Centre Ljubljana, Slovenia.

Peter Poredos (P)

Department of Anesthesiology and Perioperative Intensive Care, University Medical Centre Ljubljana, Slovenia.

Mateja Jezovnik (M)

Department of Advanced Cardiopulmonary Therapies and Transplantation, 12340University of Texas Health Science Center at Houston, TX, USA.

Debra Hoppensteadt (D)

Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.

Jawed Fareed (J)

Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.

William Hopkinson (W)

Orthopaedic Surgery and Rehabilitation Department, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH